Source: European Medicines Agency (EU) Revision Year: 2019 Publisher: GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
INTEGRILIN 0.75 mg/ml solution for infusion.
| Pharmaceutical Form |
|---|
|
Solution for infusion. Clear, colourless solution. |
Each ml of solution for infusion contains 0.75 mg of eptifibatide.
One vial of 100 ml of solution for infusion contains 75 mg of eptifibatide.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Eptifibatide |
Eptifibatide is an inhibitor of platelet aggregation and belongs to the class of RGD (arginine-glycine-aspartate)-mimetics. Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein (GP) IIb/IIIa receptors. |
| List of Excipients |
|---|
|
Citric acid monohydrate |
One 100 ml Type I glass vial, closed with a butyl rubber stopper and sealed with a crimped aluminium seal.
GlaxoSmithKline (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
EU/1/99/109/001
Date of first authorisation: 01.07.1999
Date of latest renewal: 09.07.2009
| Drug | Countries | |
|---|---|---|
| INTEGRILIN | Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, United Kingdom, United States, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
